1-20 of 275
Thomas M. Habermann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer Chapman, Christopher S Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R Flowers, Izidore S. Lossos
Journal: Blood
Blood blood.2022019294.
DOI: https://doi.org/10.1182/blood.2022019294
Published: 2023
Includes: Supplemental data
Journal Articles

Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Yucai Wang, Dai Chihara, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Victor M. Orellana-Noia, Richard Burack, Jonathan W. Friedberg, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link
Journal: Blood
Blood (2022) 140 (Supplement 1): 6642–6644.
DOI: https://doi.org/10.1182/blood-2022-157083
Published: 2022
Journal Articles

Molecular Landscape of Primary Refractory DLBCL

Allison M. Bock, Kerstin Wenzl, Matthew E. Stokes, Joseph P. Novak, Melissa A. Hopper, Jordan E. Krull, Abigail Dropik, Vivekananda Sarangi, Maria Ortiz, Nicholas Stong, C. Chris Huang, Matthew J. Maurer, Rebecca L. King, Richard Curtis Godby, Umar Farooq, Yucai Wang, Stephen M. Ansell, Thomas M. Habermann, James R. Cerhan, Anita K. Gandhi, Grzegorz (Greg) Nowakowski, Anne J. Novak
Journal: Blood
Blood (2022) 140 (Supplement 1): 9221–9223.
DOI: https://doi.org/10.1182/blood-2022-156497
Published: 2022
Journal Articles

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Matthew E Stokes, Kerstin Wenzl, C. Chris Huang, Maria Ortiz Estevez, Matthew J. Maurer, Nicholas Stong, Patrick Hagner, Yumi Nakayama, Chih-Chao Hsu, Samuel A Danziger, Fadi Towfic, Rebecca L. King, Joel S. Parker, Brian K. Link, Susan L. Slager, Vivekananda Sarangi, Yan Asmann, Joseph P. Novak, Akshay Sudhindra, Stephen M. Ansell, Thomas M. Habermann, Grzegorz S. Nowakowski, James R. Cerhan, Anne J. Novak, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3548–3550.
DOI: https://doi.org/10.1182/blood-2022-170228
Published: 2022
Journal Articles

Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

George W. Wright, Colleen A. Ramsower, James R. Cerhan, Anne J. Novak, Brian K. Link, Matthew J. Maurer, Raphael Mwangi, Allison C. Rosenthal, Thomas M. Habermann, Lou Staudt, Robert Kridel, David W. Scott, Christian Steidl, Lisa M. Rimsza
Journal: Blood
Blood (2022) 140 (Supplement 1): 6426–6427.
DOI: https://doi.org/10.1182/blood-2022-160351
Published: 2022
Journal Articles

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Karan Chohan, Saurabh Zanwar, Ronald Go, Jonas Paludo, Carrie A. Thompson, Asher Chanan-Khan, Sikander Ailawadhi, Thomas M. Habermann, Thomas E. Witzig, Morie A Gertz, Stephen M. Ansell, Shaji K Kumar, Rajiv K. Pruthi, William L. Nichols, Prashant Kapoor, Meera Sridharan, Jithma P. Abeykoon
Journal: Blood
Blood (2022) 140 (Supplement 1): 9363–9365.
DOI: https://doi.org/10.1182/blood-2022-168232
Published: 2022
Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Matthew J. Maurer, Vit K Prochazka, Christopher R. Flowers, Lasse Hjort Jakobsen, Diego Villa, Caroline E. Weibull, Elliot J. Cahn, Alexandra Smith, Herve Ghesquieres, Robert Kridel, Maher Gandhi, Chan Y. Cheah, Eliza Hawkes, John F. Seymour, Ciara L. Freeman, Michael Roost Clausen, Björn E Wahlin, Jonathan W. Friedberg, Carla Casulo, Thomas M. Habermann, Yucai Wang, Loretta J. Nastoupil, Peter De Nully Brown, David Belada, Andrea Janíková, Heidi Mocikova, Tomáš Fürst, Richard Burack, Peter Martin, Jonathon B. Cohen, Izidore S. Lossos, Brad S. Kahl, Brian K. Link, Karin E. Smedby, Laurie H. Sehn, Marek Trneny, Tarec Christoffer Christoffer El-Galaly, James R. Cerhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 2292–2295.
DOI: https://doi.org/10.1182/blood-2022-157194
Published: 2022
Journal Articles

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Reema K. Tawfiq, Melissa C. Larson, Jennifer Jane Gile, Allison M. Bock, Kittika Poonsombudlert, Seth M. Maliske, Matthew J. Maurer, James R. Cerhan, Brian Kabat, Katherine Smith, Richard Curtis Godby, Jonas Paludo, David J. Inwards, Sabarish Ayyappan, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Umar Farooq, Yucai Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6489–6491.
DOI: https://doi.org/10.1182/blood-2022-167633
Published: 2022
Journal Articles

Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL

Kerstin Wenzl, Matthew E Stokes, Joseph P. Novak, Sana Khan, Melissa A. Hopper, Jordan E. Krull, Abigail Dropik, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C. Chris Huang, Matthew J. Maurer, Lisa M. Rimsza, Brian K. Link, Susan L. Slager, Yan Asmann, Patrizia Mondello, Ryan D. Morin, Stephen M. Ansell, Thomas M. Habermann, Andrew L. Feldman, Rebecca L. King, Grzegorz S. Nowakowski, James R. Cerhan, Anita K. Gandhi, Anne J. Novak
Journal: Blood
Blood (2022) 140 (Supplement 1): 1742–1744.
DOI: https://doi.org/10.1182/blood-2022-159620
Published: 2022
Journal Articles

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Jennifer Jane Gile, Allison M. Bock, Reema K. Tawfiq, Melissa C. Larson, Kittika Poonsombudlert, Seth M. Maliske, Matthew J. Maurer, James R. Cerhan, Brian Kabat, Brianna Gysbers, Katherine Smith, Steven R Hwang, David J. Inwards, Jonas Paludo, Stephen M. Ansell, Thomas M. Habermann, Sabarish Ayyappan, Thomas E. Witzig, Grzegorz S. Nowakowski, Umar Farooq, Yucai Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6517–6519.
DOI: https://doi.org/10.1182/blood-2022-165419
Published: 2022
Journal Articles

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, Raphael Mwangi, Yucai Wang, Umar Farooq, Eric Mou, Andrew L. Feldman, Sergei Syrbu, Susan L. Slager, Grzegorz S. Nowakowski, Matthew J. Maurer, Neil E. Kay, Thomas M. Habermann, Brian K. Link, Carrie A. Thompson, James R. Cerhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 1934–1936.
DOI: https://doi.org/10.1182/blood-2022-165207
Published: 2022
Journal Articles

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Danny Luan, Chen Zhengming, Lasse Hjort Jakobsen, Matthew J. Maurer, Tarec Christoffer Christoffer El-Galaly, Loretta J. Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Izidore S. Lossos, Deborah M. Stephens, Thomas M. Habermann, Grzegorz S. Nowakowski, Nancy L. Bartlett, Jonathan W. Friedberg, Brad S. Kahl, John P. Leonard, Peter De Nully Brown, Karin E. Smedby, Mats Jerkeman, Peter Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1921–1923.
DOI: https://doi.org/10.1182/blood-2022-164692
Published: 2022
Journal Articles

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Jacqueline F Wang, Steven R Hwang, Yi Jiang, Xinyue Qi, Shijia Zhang, Sameer A. Parikh, Wei Ding, Saad S. Kenderian, Eli Muchtar, Paul J. Hampel, Jose F. Leis, Javier L Munoz, Gita Thanarajasingam, Jonas Paludo, David J. Inwards, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Neil E. Kay, Shouhao Zhou, Yucai Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9882–9884.
DOI: https://doi.org/10.1182/blood-2022-168152
Published: 2022
Journal Articles

Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study

Arushi Khurana, Raphael Mwangi, Rebecca L. King, Thomas M. Habermann, Stephen M. Ansell, James R. Cerhan, Grzegorz S. Nowakowski, Thomas E. Witzig, Matthew J. Maurer
Journal: Blood
Blood (2022) 140 (Supplement 1): 6666–6667.
DOI: https://doi.org/10.1182/blood-2022-169575
Published: 2022
Journal Articles

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Juan Pablo Alderuccio, Isildinha M Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R Chapman-Fredricks, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos
Journal: Blood
Blood (2022) 140 (Supplement 1): 9340–9341.
DOI: https://doi.org/10.1182/blood-2022-162688
Published: 2022
Journal Articles

A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Herve Ghesquieres, Youenn Drouet, Susan L. Slager, Franck Morschhauser, Sara Galimberti, Dennis P. Robinson, Emilie Thomas, Anne J. Novak, Luc Xerri, Stefano Luminari, Aurelie Verney, Camille Laurent, Lisa M. Rimsza, Thomas M. Habermann, Massimo Federico, Brian K. Link, Gilles Salles, James R. Cerhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 1307–1309.
DOI: https://doi.org/10.1182/blood-2022-167466
Published: 2022
Journal Articles

How I treat cardiovascular complications in patients with lymphoid malignancies

Joerg Herrmann, Kristen B. McCullough, Thomas M. Habermann
Journal: Blood
Blood (2022) 139 (10): 1501–1516.
DOI: https://doi.org/10.1182/blood.2019003893
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Allison C. Rosenthal, Colleen Ramsower, Raphael Mwangi, Matthew J. Maurer, Diego Villa, Timothy J. McDonnell, Andrew L. Feldman, Thomas M. Habermann, Jonathon B. Cohen, Ryan S. Robetorye, Elías Campo, Eva Giné, James R. Cook, Brian T. Hill, Philipp Raess, German Ott, Alexander Reichart, David W. Scott, Lisa M. Rimsza
Journal: Blood
Blood (2021) 138 (Supplement 1): 3517.
DOI: https://doi.org/10.1182/blood-2021-151275
Published: 2021
Journal Articles

Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

Xavier Andrade-Gonzalez, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards, Jonas Paludo, Thomas M. Habermann, Grzegorz S. Nowakowski, Yucai Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3549.
DOI: https://doi.org/10.1182/blood-2021-151952
Published: 2021
Journal Articles

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, Paul A S Fishkin, W. Christopher Ehmann, Timothy S. Fenske, Michael E. Williams
Journal: Blood
Blood (2021) 138 (Supplement 1): 815.
DOI: https://doi.org/10.1182/blood-2021-152976
Published: 2021